{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.6.3', 'Suitability of Subject Population', 'Although response rates to first-line chemotherapy remain high with platinum-based', 'regimens, time to disease recurrence is short in extensive-stage SCLC. Rovalpituzumab', 'tesirine has demonstrated anti-tumor activity in relapsed/refractory SCLC population.', 'Exploring rovalpituzumab tesirine in ED SCLC subjects with stable disease or objective', 'response following first-line chemotherapy is acceptable considering observed', 'activity/toxicity profile of rovalpituzumab tesirine, and that the standard approach in this', 'setting is no treatment until progression.', '5.6.4', 'Selection of Doses in the Study', 'In a recent Phase 1 study (SCRX16-001) with rovalpituzumab tesirine, the maximum', 'tolerated dose (MTD) was established at 0.4 mg/kg every 3 weeks based on the incidence', 'of Cycle 1 toxicities, while the recommended Phase 2 dose (RPTD) in SCLC was chosen', 'as 0.3 mg/kg every 6 weeks for a total of two doses with the allowance to retreat at the', 'same dose level and schedule upon progression. The RPTD is based on the toxicity and', 'efficacy profile during multiple cycles dosing (AbbVie Stemcentrx data on file). This', 'experience included multiple doses of rovalpituzumab tesirine at a) 0.2 mg/kg every', '6 weeks, b) 0.3 mg/kg every 6 weeks or c) 0.3 mg/kg every 6 weeks for a total of', 'two doses and then at 0.1 mg/kg every 6 weeks thereafter. Based on the totality of the', 'experience with rovalpituzumab tesirine and taking into consideration its pharmacokinetic', 'characteristics, dosing of 0.3 mg/kg q6wk for 2 cycles, omitting every third cycle will be', 'used in this study. This study will not exceed a maximum dose of 1.5 mg/kg at each dose.', '6.0', 'Complaints', 'A complaint is any written, electronic, or oral communication that alleges deficiencies', 'related to the physical characteristics, identity, quality, purity, potency, durability,', 'reliability, safety, effectiveness, or performance of a product/device after it is released for', 'distribution.', '75']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'The investigational product in this study is defined as rovalpituzumab tesirine or placebo', 'and dexamethasone or placebo. Complaints associated with any component of this', 'investigational product must be reported to the Sponsor (Section 6.2.2). For AEs, please', 'refer to Sections 6.1.1 through 6.1.6. For product complaints, please refer to Section 6.2.', '6.1', 'Medical Complaints', 'The investigator will monitor each subject for clinical and laboratory evidence of adverse', 'events on a routine basis throughout the study. The investigator will assess and record', 'any adverse event in detail including the date of onset, event diagnosis (if known) or', 'sign/symptom, severity, time course (end date, ongoing, intermittent), relationship of the', 'adverse event to blinded investigational product, and any action(s) taken. For serious', 'adverse events considered as having \"no reasonable possibility\" of being associated with', 'blinded investigational product, the investigator will provide an Other cause of the event.', 'For adverse events to be considered intermittent, the events must be of similar nature and', 'severity. Adverse events, whether in response to a query, observed by site personnel, or', 'reported spontaneously by the subject will be recorded.', 'All adverse events will be followed to a satisfactory conclusion.', '6.1.1', 'Definitions', '6.1.1.1', 'Adverse Event', 'An adverse event (AE) is defined as any untoward medical occurrence in a patient or', 'clinical investigation subject administered a pharmaceutical product and which does not', 'necessarily have a causal relationship with this treatment. An adverse event can therefore', 'be any unfavorable and unintended sign (including an abnormal laboratory finding),', 'symptom, or disease temporally associated with the use of a medicinal (investigational)', 'product, whether or not the event is considered causally related to the use of the product.', 'Such an event can result from use of the drug as stipulated in the protocol or labeling, as', 'well as from accidental or intentional overdose, drug abuse, or drug withdrawal. Any', 'worsening of a pre-existing condition or illness is considered an adverse event.', '76']\n\n###\n\n", "completion": "END"}